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INTRODUCTION 
Hyperglycemia, advanced glycation end-product, increased po-
lyol pathway, oxidative stress, and the activation of transform-
ing growth factor-β1 (TGF-β1) are interrelated in the pathogen-
esis of diabetic nephropathy.1 Achieving the best metabolic 
control, treating hypertension, and treating dyslipidemia are ef-
fective strategies for preventing the development of microal-
buminuria and delaying progression to more advanced stages 
of nephropathy in patients with diabetes.2 However, the above 
measures might not be effective in some patients with diabe-
tes, and novel therapeutic strategies are warranted.2 
Vitamin A is converted to two active forms, trans and cis, 
and enters the nucleus after a heterodimer of retinoic acid A re-
ceptor (RAR) and the retinoic X receptor (RXR) forms in cellu-
lar cytoplasm. By stimulating the transcription of the retinoic 
acid response element, this complex is known to exhibit anti-
proliferative and anti-inflammatory effects.3 When all-trans reti-
noic acid (ATRA), a pan-retinoic acid agonist, is administered 
orally to anti-Thy nephropathy model rats, it suppresses inter-
stitial proliferation and glomerular inflammation and prevents 
renal damage.4 Moreover, retinoic acid has been reported to 
block lipid peroxidation in streptozocin-induced diabetic rats, 
and there are studies that also support the protective effect of 
retinoic acid on the progression of diabetic nephropathy.5 
In this study, we aimed to examine the effect of ATRA on di-
abetic nephropathy by measuring the amount of urinary albu-
min excretion (UAE) after administrating ATRA to Otsuka Long-
Evans Tokushima Fatty (OLETF) rats, a model of spontaneous 
late onset type 2 diabetes mellitus (T2DM), which is associat-
ed with obesity, insulin resistance, and impaired insulin se-
cretion.6 In order to understand the mechanism of action for 
ATRA, we administered ATRA to cultured rat mesangial cells 
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(RMCs) to examine its effect on TGF-β1 expression after veri-
fying increased expression of TGF-β1 in response to high glu-
cose media, compared to RMCs cultured in control glucose 
media. Moreover, after the administration of ATRA, we exam-
ined changes in protein kinase C (PKC) and reactive oxidative 
system (ROS), both of which are located upstream in the in-
tracellular signaling pathway of TGF-β1. 
 
MATERIALS AND METHODS 
Animal study and experimental design
Six-week old male OLETF and Long-Evans-Tokushima-Otsu-
ka (LETO) rats were obtained as a generous gift from the To-
kushima Research Institute, Otsuka Pharmaceutical, Tokushi-
ma, Japan. Each rat was housed in a metabolic cage and ma-
intained on a 12-h light-dark cycle at 24°C and 40–60% humi-
dity. Tap water and pelleted rat chow were available ad libitum 
throughout the experiments. We measured the body weight of 
the rats every 4 weeks after an overnight fast.
Fasting blood glucose (Hexokinase method, Advia® 1650, 
Bayer, Berkley, MI, USA) levels were measured at 28 weeks of 
age, utilizing whole blood obtained from the tail vein after over-
night fasting. An oral glucose tolerance test (2 gram glucose per 
kg body weight) was performed at 28 weeks of age for the diag-
nosis of diabetes, and blood glucose levels were measured be-
fore and 2 hours after administering the glucose load.
From 28 weeks of age, we orally administered 10 mg/kg body 
weight of ATRA (Promega, Madison, WI, USA) dissolved in 
cellulose and 5% Dimethyl sulfoxide (DMSO) to 20 OLETF rats 
with diabetes for 16 weeks (ATRA-treated OLETF group). We 
administered cellulose and DMSO as a vehicle to 20 OLETF 
rats (non-treated OLETF group) and 10 LETO rats (LETO group) 
for the same period. 
At 44 weeks of age, the rats were anesthetized with tiletami-
ne/zolazepam (Zoletin®, 30 mg/kg, intraperitoneally, Virbac 
Lab., Carros, France), as well as xylazine (Rompen® 10 mg/kg, 
intraperitoneally, Bayer, Berkley, MI, USA), and blood sam-
ples were subsequently collected via cardiac puncture. We 
measured serum glucose (Hexokinase method, Advia® 1650, 
Bayer, Berkley, MI, USA), C-peptide (Radioimmunoassay, 
RAT C-peptide RIA kit, Linco, St. Charles, MO, USA), insulin 
(Radioimmunoassay, RAT Insulin RIA kit, Linco, St. Charles, 
MO, USA), total cholesterol (Enzymatic assay, Advia® 1650, 
Bayer, Berkley, MI, USA), triglyceride (Enzymatic assay, Ad-
via® 1650, Bayer, Berkley, MI, USA), high density lipoprotein 
cholesterol (HDL-C, Selective inhibition method, Advia® 1650, 
Bayer, Berkley, MI, USA), and low density lipoprotein choles-
terol (LDL-C, calculated by total cholesterol–triglyceride× 
0.456–HDL-C). For the evaluation of adverse reactions, we ex-
amined peripheral blood (LH 750, Coulter, Miami, FL, USA) af-
ter overnight fasting for serum creatinine (Jaffe, Alkaline Pic-
rate, Kinetic method, Advia® 1650, Bayer, Berkley, MI, USA), 
aspartate aminotransferase (IFCC UV method, Advia® 1650, 
Bayer, Berkley, MI, USA), and alanine aminotransferase (IFCC 
UV method, Advia® 1650, Bayer, Berkley, MI, USA) levels. Tw-
enty-four hour urine samples were collected at 44 weeks of age, 
and albumin excreted into the urine was measured by an im-
munoturbidimetric method (Cobas Integra, Roche, Basel, Swi-
tzerland) using rat albumin as a standard. For a control group, 
we kept the LETO rats under the same conditions and perfor-
med the same tests. All procedures were performed according 
to institutional guidelines for animal research.
 
Culture of rat mesangial cells (RMCs) 
We cultured commercial RMCs in Dulbecco’s Modified Eagle 
Medium (DMEM), low glucose (1 g/L), 1% penicillin, and 5% 
fetal bovine serum, and we exchanged the culture media ev-
ery 2–3 days for 2 weeks. When RMCs approached confluence, 
they were subcultured using trypsin/EDTA (0.5%/0.53 nM). 
The RMCs were utilized at 6–10 cycles of subculture for the fol-
lowing experiments. 
To examine the effect of high glucose on RMC, D-glucose 
(Sigma Chemical Co., St. Louis, MO, USA) was added to DMEM 
to final glucose concentrations of 30 and 5 mM for the high 
glucose and control glucose groups, respectively. To exclude 
an osmolar effect of high glucose concentration, we added 25 
mM of mannitol to the media containing 5 mM of glucose.
After incubation of quiescent RMCs with 10-8, 10-7, 10-6, and 
10-5 M ATRA for the given time periods (6, 24, and 48 hrs) in 
media containing 30 or 5 mM glucose, changes in TGF-β1 and 
PKC expression and ROS were measured. 
 
Measuring TGF-β1, PKC, ROS
Culture media was collected and centrifuged. The cell suspen-
sion was activated using 1 N HCl and 1.2 N NaOH, and we 
measured concentrations of TGF-β1 using the quantitative 
sandwich enzyme immunoassay technique from R&D system 
(Minneapolis, MN, USA). The expression of PKC isoforms was 
determined using Western blot analysis. In brief, we washed 
the culture cells (5×106–1×107) with PBS buffer two times and 
suspended them in 0.5 mL of whole cell lysate buffer. Equal 
amounts of protein were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) (8% resolv-
ing), electro-blotted to nitrocellulose, and probed with anti-
bodies against PKC-α, -β, -δ (1:500 dilution, Santa Cruz, CA, 
USA), or β-actin (1:5000 dilution, Sigma, St. Louis, MO, USA) 
overnight in a 4°C cold room. The proteins were visualized by 
chemiluminescent detection [electrochemiluminescence (ECL), 
Amersham Biosciences, Bucks, UK]. To measure ROS, a per-
oxidase-sensitive fluorescent indicator, 2’,7’-dichlorofluo-
rescin diacetate (DCF, 10 mmol/L; Molecular Probes Inc., Eu-
gene, OR, USA) was incubated with mesangial cells for 30 
minutes. The cells were then washed and fluorescence was 
quantified. ROS oxidizes the probe forming the compound, 
2’,7’-dichlorofluorescin. Fluorescence was quantified using an 
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E-max enzyme-linked immunosorbent assay (ELISA) reader 
(Molecular Device Corp., Sunnyvale, CA, USA). 
Statistical analyses 
Results are expressed as mean±SD or SE, with n as the num-
ber of experiments. The Kruskal-Wallis multiple comparison 
nonparametric test [or analysis of variance (ANOVA)] was per-
formed, and a post hoc analysis was applied to determine in-
dividual differences between means. Changes in the various 
parameters following the administration of ATRA at different 
concentrations and with different treatment periods were an-
alyzed using trend analysis (linear by linear association meth-
od). A p-value of <0.05 was considered significant. All statistical 
analyses were performed using SPSS software for Windows, 
version 11.5 (SPSS Inc., Chicago, IL, USA).
RESULTS 
In vivo study
There was no significant difference in weights among the 
three groups prior to 28 weeks of age. After 28 weeks of age, 
the OLETF rats weighed more than LETO rats of the same age, 
while there was no statistical difference in weights between 
the non-treated OLETF rat group and the ATRA-treated OLETF 
rat group (Fig. 1). 
At 28 weeks of age, immediately before the administration 
of ATRA, fasting glucose was significantly lower in the LETO 
rats than in the OLETF rats (6.42±0.54 mmol/L, p<0.01). A post-
prandial 2-hr glucose level was also significantly lower in the 
LETO rats (7.99±0.37 mmol/L), compared to the OLETF rats 
(18.59±0.54 mmol/L, p<0.01). However, both fasting (6.56± 
0.51 mmol/L vs. 6.30±0.57 mmol/L) and postprandial 2-hr 
(19.6±4.50 mmol/L vs. 17.8±3.07 mmol/L) blood glucose lev-
els were not different between the non-treated and ATRA-
treated OLETF rats.
At 44 weeks of age, 16 weeks after the administration of 
ATRA was initiated, fasting glucose was significantly lower in 
the LETO rats than in the OLETF rats (p<0.01). Serum glucose 
levels were also significantly different in the ATRA-treated 
OLETF rats, compared to the non-treated OLETF rats (p<0.05). 
Compared with the LETO rats, the non-treated OLETF and the 
ATRA-treated rats had increased concentrations of total cho-
lesterol (all p<0.01) and triglyceride. However, no significant 
differences in total cholesterol and triglyceride were found be-
tween the ATRA-treated OLETF rats and the non-treated OL-
ETF rats. There were no significant differences in HDL-C and 
LDL-C levels between the three groups. Non-treated OLETF 
rats exhibited higher insulin, C-peptide, and homeostasis mod-
el assessment for insulin resistance (HOMA-IR) levels than 
the other two groups, which is consist with increased insulin 
resistance. Twenty four-hour urine volumes were lower in the 
LETO rats than the non-treated and ATRA-treated OLETF rats 
(all p<0.01). The OLETF rats exhibited a higher daily UAE than 
the LETO rats at 44 weeks of age. In the ATRA-treated OLETF 
rats, daily UAE was lower than in the non-treated OLETF rats 
(p<0.01). There were no significant differences in liver enzymes, 
creatinine, hemoglobin level, white blood cell count, or platelet 
count between the three groups (Table 1). 
Effect of ATRA on TGF-β1 in the RMCs 
From conditioned media, RMCs exhibited a time-dependent 
increase in TGF-β1 levels after being incubated in the presence 
of both 30 and 5 mM glucose conditions. Compared with the 
control glucose concentration, incubation in a high glucose 
concentration significantly increased TGF-β1 secretion at 24 
and 48 hours, with TGF-β1 levels reaching 578.3±23.1 [mean± 
standard error of the mean (SEM) of three experiments] and 
651.2±29.7 pg/mL for control glucose and 798.0±39.8 and 
887.4±43.7 pg/mL for high glucose concentration (p<0.05), re-
spectively. 
In addition, treatment with ATRA under both 30 and 5 mM 
glucose conditions exhibited dose and time-dependent de-
creases in TGF-β1 levels (all p<0.05) (Fig. 2). 
 
Effect of ATRA on PKC expression in the RMCs 
The media showed a time-dependent increase in PKC expres-
sion under both control and high glucose conditions. The in-
crease in PKC expression was observed at 12 hrs and reached 
a maximum at 24 hrs. Treatment with ATRA under both con-
trol and high glucose conditions showed a dose-dependent de-
crease in PKC expression. Our findings demonstrated de-
Fig. 1. Body weight of rats from 10 to 44 weeks of age. There was no sig-
nificant difference in weights among the three groups prior to 28 weeks. 
After 28 weeks of age, the OLETF rats weighed more than the LETO rats 
of the same age, while there was no statistical difference in weights be-
tween the non-treated OLETF rat group and the ATRA-treated OLETF rat 
group. A statistical difference was determined between groups with the 
same duration of treatment period. White circle: non-treated OLETF rat, 
black circle: ATRA-treated OLETF rat, white square: LETO rat. *p<0.01 ver-
sus the LETO rats. OLETF, Otsuka Long-Evans Tokushima Fatty; LETO, 
Long-Evans-Tokushima-Otsuka; ATRA, all-trans retinoic acid.
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creased PKC expression in the RMCs by ATRA (Fig. 3).
 
Effect of ATRA on ROS generation in the RMCs
ATRA at 10-6 and 10-5 M significantly decreased DCF-sensitive 
cellular ROS levels, compared with the control condition. 
DCF-sensitive cellular ROS in the RMCs showed a time-de-
pendent decrease after ATRA administration (Fig. 4A). In ad-
dition, after incubating the synchronized quiescent RMCs with 
10-5 M ATRA in media containing 30 or 5 mM glucose for dif-
ferent time periods (6, 12, and 48 hrs), a relative decrease in ROS 
was seen. DCF-sensitive cellular ROS in the RMCs showed a 
time-dependent decrease after ATRA administration (Fig. 4B). 
DISCUSSION 
 
In this study, we demonstrated that ATRA treatment decreases 
albuminuria and suppresses TGF-β1 synthesis. ATRA is known 
to exert beneficial effects on nephropathy.7-9 ATRA treatment 
has been shown to limit glomerular cell proliferation and renal 
damage by reducing renal TGF-β1 and TGF receptor II expres-
sion in nephropathy rat models.4 ATRA treatment also exhib-
its an anti-oxidant effect by blocking lipid peroxidation in 
streptozotocin-induced diabetic rats.5 In a diabetic rat model, 
treatment with ATRA caused a drop in urinary protein excre-
tion.8 ATRA regulates the expression of multiple genes by bind-
ing to and subsequently activating RAR α, β, and γ and/or RXR 
α, β, and γ.9 The binding of ATRA or other retinoids to the re-
ceptors causes the dissociation or release of corepressors and 
recruitment of coactivators to prompt and facilitate gene tran-
scription.10 It is speculated that the therapeutic effect of ATRA 
in animal models of nondiabetic renal disease may be linked 
to down-regulation of genes related to inflammation, cell pro-
liferation, and fibrosis.11 However, the exact mechanism of its 
protective effect on diabetic nephropathy has not yet been elu-
cidated. In the study of Han, et al.,8 ATRA generated renopro-
tective effects through reduction of the renal inflammatory 
process. In that study, they investigated ATRA’s renoprotective 
effects for a relatively short time (4 weeks) in the early stages 
of diabetic nephropathy,8 while on the other hand, we evalu-
ated the effects of ATRA from the time albuminuria became 
prominent12 for a longer term treatment (16 weeks). Even 
though repeated oral administration of ATRA may cause autoin-
duced metabolism of the drug and a decrease in plasma con-
centrations, intravenous administration may have potential 
advantages over oral ATRA and may be more efficacious.13 
TGF-β1 stimulates the transcription of many extracellular 
matrix genes in renal cells.14 In several models of renal disease 
(e.g., diabetic nephropathy, experimental glomerulonephritis, 
or unilateral ureteral obstruction), TGF-β1 has been implicat-
ed as a primary mediator for cell growth and accumulation of 
extracellular matrix.15 TGF-β1 might be a critical mediator for 
diabetic nephropathy. Interrupting this system may hold 
promise for amelioration of diabetic nephropathy. Existing ap-
proaches to renoprotection, including glycemic control, low-
ering dietary protein, and the administration of angiotensin 
Table 1. Biochemical Data of Control and Diabetic Rats at 44 Weeks of Age
LETO rats Non-treated OLETF rats ATRA-treated OLETF rats
Fasting glucose (mmol/L) 5.85±0.80 9.91±2.13† 8.38±1.39†‡
TC (mmol/L) 2.87±0.20 5.15±1.53† 4.24±1.65†
Triglyceride (mmol/L) 0.30±0.17 2.61±1.68† 2.28±0.85†
HDL-C (mmol/L) 1.42±0.36 1.42±0.41 1.25±0.33
LDL-C (mmol/L) 1.62±0.18 2.53±1.17 2.00±1.34
Insulin (pmol/L) 10.26±4.02 17.15±2.44† 13.85±5.31‡
C-peptide (pmol/L) 0.26±0.06 0.35±0.18 0.25±0.19
HOMA-IR 0.37±0.13 1.06±0.28† 0.73±0.32*‡
Urine amount (mL/day) 17.7±3.0 37.7±18.8† 30.4±9.7†
Urine albumin (mg) 0.15±0.07 2.42±2.15† 0.96±0.52*‡
Urine creatinine (mg) 13.9±2.1 15.2±3.2 14.6±2.8
UAE (mg/mgCr) 0.01±0.01 0.17±0.15† 0.07±0.03*§
Creatinine (μmol/L) 84.23±11.53 78.03±7.98 73.59±13.30
AST (μkat/L) 1.07±0.56 1.24±0.70 1.13±0.43
ALT (μkat/L) 0.94±0.15 0.92±0.30 1.02±0.33
Hemoglobin (g/L) 0.14±0.10 0.14±0.09 0.14±0.11
WBC (109/L) 2.28±1.68 3.28±1.45 3.17±1.48
Platelet (109/L) 725.3±212.1 829.1±231.8 905.1±84.1
LETO, Long-Evans-Tokushima-Otsuka; OLETF, Otsuka Long-Evans Tokushima Fatty; ATRA, all-trans retinoic acid; TC, total cholesterol; HDL-C, high density lipopro-
tein cholesterol; LDL-C, low density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment for insulin resistance; UAE, urine albumin excretion; AST, 
aspartate aminotransferase; ALT, alanine aminotransferase; WBC, white blood cell. 
Values are expressed as mean±SD, statistical difference was performed among groups with the same duration of experimental period. 
*p<0.05 versus the LETO rat, †p<0.01 versus the LETO rats, ‡p<0.05 versus the non-treated OLETF rats, §p<0.01 versus the non-treated OLETF rats. 
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conversion enzyme inhibitors and angiotensin receptor block-
ers, may act, at least in part, via the inhibition of TGF-β1. ATRA 
have been previously shown to down-regulate TGF-β1 gene 
expression via activator protein-1 (AP-1) binding sites on the 
TGF-β1 promoter.16 Furthermore, Morath, et al.4 demonstrated 
that the beneficial effects of ATRA on glomerular damage were 
presumably due to a marked reduction in renal TGF-β1 and 
TGF receptor II expression. Similarly, in our study, treatment 
with ATRA caused a dose- and time-dependent decrease in 
TGF-β1 production in the RMCs. As in previous studies, our 
present observations suggest that ATRA treatment may exert 
beneficial effects on diabetic renal disease by inhibiting TGF-β1 
production.
In our study, we have shown that high glucose-induced PKC 
expression is effectively inhibited by ATRA administration. 
The inappropriate activation of PKC has been implicated as a 
putative mediator in the pathogenesis of diabetic nephropa-
thy based on evidence from both in vivo experimental animal 
diabetic models and in vitro studies with cultured glomerular 
cells.17 Activation of PKC contributes to increased accumula-
tion of microvascular matrix protein by inducing the expres-
sion of TGF-β1 in both cultured mesangial cells18 and the glom-
eruli of diabetic rats.19 PKC-α, β, δ, and ε are activated in the glo-
meruli of diabetic rats.20 Inhibition of PKC-β is nephroprotective 
in a diabetic model.21 Treatment with ruboxistaurin mesylate, 
PKC inhibitor, in genetically diabetic mice prevented mesan-
gial expansion and glomerular dysfunction.22 Retinoids can 
Fig. 2. Effect of ATRA on TGF-β1 protein. (A) After the incubation of quies-
cent mesangial cells in media containing 30 (high) or 5 mM (control) glu-
cose and different concentrations of ATRA. Treatment with ATRA under 
both 30 and 5 mM glucose conditions was associated with dose-depen-
dent decreases in TGF-β1 levels (p<0.05 by a test for a trend). (B) After the 
incubation of quiescent rat mesangial cells with 10-5 M ATRA for the given 
periods (6, 24, and 48 hrs) in media containing 30 or 5 mM of glucose. 
Treatment with ATRA under both 30 and 5 mM glucose conditions 
showed time-dependent decreases in TGF-β1 levels (p<0.05 by a test for a 
trend). Values are expressed as mean±SEM of three separate experi-
ments. *p<0.05 compared to the vehicle, i.e., without ATRA, †p<0.05 com-
pared with 0 hour. TGF-β1, transforming growth factor-β1; ATRA, all-trans 
retinoic acid; SEM, standard error of the mean.
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function as antioxidants and promote differentiation, provid-
ing a protective effect against altered activation of PKC.23 In 
fact, retinoic acid reduced or inactivated PKC in many stud-
ies.24 PKC activation might regulate the expression of TGF-β1 
at a transcriptional level, since its promoter contains AP-1 sites. 
AP-1 sites are activated by the proto-oncogene complexes, fos-
jun homodimers or heterodimers.22 Retinoid suppresses im-
portant inflammatory transcriptional factors, AP-1, by activa-
tion of the RXR.25 Therefore, we can infer that the beneficial 
effect of ATRA on diabetic nephropathy could be due to either 
its ability to directly inactivate PKC or through the suppres-
sion of TGF-β1. However, to clarify its mechanism, further in-
vestigation is needed. 
In this study, we have demonstrated that high glucose con-
centration induces ROS in the RMCs. Moreover, we showed 
that high glucose concentration-induced ROS generation in 
the RMCs was effectively blocked by ATRA in a dose- and time-
dependent manner. Increased ROS production is an important 
mechanism proposed to explain why poor glycemic control in 
diabetes results in vascular complications.26 High glucose 
concentration induces ROS27 and up-regulates TGF-β128 ex-
pression in glomerular mesangial cells. ROS also up-regulates 
TGF-β1 expression in mesangial cells.29 Along with previous 
studies, our present observations suggest that ATRA treatment 
may exert beneficial effects on diabetic renal disease by low-
ering blood glucose concentrations and inhibiting TGF-β1 pro-
duction through the inhibition of PKC expression and ROS 
synthesis in mesangial cells.
The beneficial effects of ATRA on diabetic nephropathy in 
our study might have been due to the antihypertensive effect of 
ATRA. Besides hyperglycemia, hypertension is another poten-
tially modifiable factor to prevent the initiation and progres-
sion of diabetic nephropathy in susceptible individuals.30 The 
antihypertensive mechanism of ATRA has not yet been clari-
fied, but has been considered to include the alleviation of renal 
damage by retinoic acid and blockade of angiotensin II ac-
tion.31 Although we did not measure blood pressure in the ex-
perimental rats, it has been reported that most of the antihyper-
tensive effect of retinoids are observed in acute and chronic 
experimental nephritic rat models.9
Diabetic nephropathy is the leading cause of end stage re-
nal disease, requiring dialysis treatment. Diabetic nephropa-
thy is developed 25 years after the onset of diabetes among 25–
40% of diabetic patients.32 Based on the cumulative epidemio-
logical data, it is obvious that the maintaining normoglycemia 
is the most effective method to prevent and delay the diabetic 
nephropathy.33 However, from these epidemiological studies, it 
is also evident that the long-term maintenance of normoglyce-
mia is difficult in most subjects with diabetes. Therefore, efforts 
have been directed to identify the therapeutic plans that could 
abolish diabetic nephropathy development and progression.
In conclusion, our findings in the present study provide evi-
dence that ATRA treatment can influence the development of 
diabetic nephropathy without causing any obvious adverse 
effects. The beneficial effects of ATRA on diabetic nephropa-
thy in the RMCs were in part due to reduction of TGF-β1 syn-
thesis, which was mediated by a significant reduction of PKC 
activity and ROS production. Also, our findings highlight the 
need for further studies to assess the potential therapeutic ef-
fects of ATRA in diabetic nephropathy, to delineate the mecha-
nism of action for ATRA, and to identify retinoid receptor-spe-
cific pathways in the kidney. 
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